InVivo Biosystems

Company profile

InVivo Biosystems company profile

InVivo Biosystems is a biotechnology company that provides genome editing and in vivo analytical services to accelerate drug discovery and development. The company specializes in creating custom genome-edited C. elegans and zebrafish models to support research in neurological, metabolic, and rare monogenic diseases.​ Founded through the merger of NemaMetrix and Knudra Transgenics, InVivo Biosystems has developed proprietary technologies, including the RapidGen™ preclinical platform, to bridge the gap between cell culture and rodent models. This platform enables early-stage compound screening, toxicity testing, and efficacy analysis, providing biologically relevant data to inform critical decisions in the drug development process.​ The company serves pharmaceutical, nutraceutical, biotechnology companies, and academic research institutions, offering services such as CRISPR genome editing, zebrafish toxicity testing, and compound efficacy testing . InVivo Biosystems holds multiple global patents for its genome editing technologies and continues to innovate in the field of preclinical development.​